OCPs are absolutely contraindicated in:
**Core Concept**
OCPs (Oral Contraceptive Pills) are a form of hormonal contraception that combine estrogen and progesterone to prevent ovulation and pregnancy. Certain medical conditions and patient factors necessitate caution or contraindication of OCPs to prevent adverse outcomes.
**Why the Correct Answer is Right**
The correct answer is related to a condition that significantly increases the risk of thromboembolic events, such as deep vein thrombosis and pulmonary embolism, when combined with the estrogen component of OCPs. This is because estrogen can increase blood coagulability and thrombin generation, thereby increasing the risk of clot formation. Women with a history of venous thromboembolism (VTE) are at a higher risk of developing recurrent VTE when taking OCPs containing estrogen.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because, while smoking is a risk factor for VTE, it is not an absolute contraindication for OCPs. Smoking can increase the risk of VTE, but this risk can be mitigated by choosing OCPs that contain lower doses of estrogen or by using alternative forms of contraception.
**Option B:** This option is incorrect because breast cancer is not an absolute contraindication for OCPs. In fact, some studies suggest that OCPs may have a protective effect against breast cancer, particularly for women who start taking them at a younger age.
**Option C:** This option is incorrect because hypertension is not an absolute contraindication for OCPs. While OCPs can increase blood pressure, this effect is generally mild and temporary, and most women with hypertension can safely use OCPs.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that OCPs are contraindicated in women with a history of VTE, particularly if the VTE occurred at a young age or in the context of other risk factors such as smoking or obesity. This is because estrogen-containing OCPs can significantly increase the risk of recurrent VTE.
**Correct Answer: D. History of Venous Thromboembolism.**